Proxy Votes Now

Home › Activist investors › Shah Capital

Shah Capital

Campaign activist. Positions and campaigns from Shah Capital’s SEC filings. Updated November 20, 2026.

Filer entities
SHAH CAPITAL MANAGEMENT
SEC CIK
1383838 (SHAH CAPITAL MANAGEMENT)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Oct 9, 2026: 11 US-listed positions reported; 2 of 1% or more of a company without a 13D are listed below.
4current positions
3new or changed in 90 days
0active campaigns
2campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (4)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Novavax, Inc. 6.5%10,656,964 shares Schedule 13D/A, filed Oct 16, 2026 Apr 15, 2024 Decreased Oct 16, 2026 ▼ 2.57 pts Decreased Standard Item 4 language
Elicio Therapeutics, Inc. 4.42%1,250,000 shares 13F, quarter ended Sep 30, 2026filed Oct 9, 2026; % of shares outstanding as of Nov 3, 2026 Oct 9, 2026 — — New 13F: none stated
Tronox Holdings PLC 1.83%2,915,807 shares 13F, quarter ended Sep 30, 2026filed Oct 9, 2026; % of shares outstanding as of Oct 20, 2026 Nov 12, 2025 Increased Oct 9, 2026 ▲ 0.22 pts Increased 13F: none stated
VEON Ltd. 6.7%4,620,275 shares Schedule 13D/A, filed Oct 16, 2026 Oct 31, 2023 Increased Oct 21, 2024 ▼ 0.29 pts — Standard Item 4 language

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Novavax, Inc. · Standard Item 4 language

“Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission. Consequently, Shah Capital no longer operates as a registered investment adviser, and the Reporting Persons have updated their regulatory status accordingly. As a result, the Reporting Persons no longer hold the shares”

Item 4 in the Schedule 13D/A filed Oct 16, 2026.

Summary of the filing Shah Capital withdrew its investment-adviser registration and says it no longer holds its Novavax stake with intent to influence control, planning to move to Schedule 13G.

Quoted from the filing (item 4): “Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission.” Oct 16, 2026

VEON Ltd. · Standard Item 4 language

“Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission. Consequently, Shah Capital no longer operates as a registered investment adviser, and the Reporting Persons have updated their regulatory status accordingly. As a result, the Reporting Persons no longer hold the shares”

Item 4 in the Schedule 13D/A filed Oct 16, 2026.

Summary of the filing Shah Capital restructured into a family office, deregistered as an investment adviser, and says it will report on Schedule 13G going forward with no present activism plans.

Quoted from the filing (item 4): “the Reporting Persons no longer hold the shares with a purpose of influencing control and intend to report on Schedule 13G going forward” Oct 16, 2026

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (2)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Novavax, Inc.Board seatsGovernance changes Shareholder meeting held after the soliciting material Jun 17, 2026 Apr 27, 2023 Proxy contest filed (preliminary proxy) latest (12) —
Vitamin Shoppe, Inc.Board seats Settled (agreement with the company) Apr 23, 2018 Apr 23, 2018 — latest (3) —
Past positions (1)
CompanyLast stakeSourceOutcomeDate
Emeren Group Ltd 0.0% Schedule 13D/A, filed Dec 16, 2025 Exited Dec 16, 2025

How large managers voted in Shah Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Settlement
1No outcome in the filings read
Outcome of each campaign (2)
CompanyOutcomeDetailDateFirst filing
Novavax, Inc. No outcome in the filings read — Jun 17, 2026 Apr 27, 2023
Vitamin Shoppe, Inc. Settlement agreement with the company May 15, 2018 Apr 23, 2018

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Vitamin Shoppe, Inc. · Apr 23, 2018 · Directors named, Board seats, Voting commitment

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Shah Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Tronox Holdings PLC · Shah Capital first disclosed Nov 12, 2025 · 3 other filings
HolderFormDateStake
FMR LLC Schedule 13G Jun 6, 2025 0.2%
Dimensional Fund Advisors LP Schedule 13G Oct 9, 2025 5.0%
The Vanguard Group Schedule 13G Oct 31, 2025 6.2%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.